Melanoma is the most aggressive type of skin cancer and is responsible for the majority of deaths from skin cancer. Therapeutic advances in the last few decades, notably the development of novel targeted therapies and immunotherapies have significantly improved patient outcomes; nonetheless, these options remain limited due to the onset of resistance to treatment modalities and relapse. In this review, we focus on the available therapeutic options, their benefits, and limitations.
Keywords: drug resistance; immunotherapy; melanoma; metabotropic glutamate receptor type 1; molecular targeted therapy; riluzole; skin neoplasms.
© 2023 The Authors. Pigment Cell & Melanoma Research published by John Wiley & Sons Ltd.